One stock that could ride the market rally is CRISPR Therapeutics (NASDAQ: CRSP). This biotech is seeking to develop breakthrough therapies for difficult-to-treat illnesses using gene editing, and the company's focus in this area earned it a prominent place in the Ark Genomic Revolution ETF, an exchange-traded fund overseen by Cathie Wood. Wood isn't the only one on Wall Street who likes CRISPR.